Elizabeth G Demicco1,2, Khalida Wani3, Davis Ingram3, Michael Wagner4, Robert G Maki5,6, Anthony Rizzo7, Alan Meeker7, Alexander J Lazar3,8, Wei-Lien Wang3. 1. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada. 2. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 3. Pathology and Translational Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. 4. Division of Medical Oncology, University of Washington, Seattle, WA, USA. 5. Northwell Cancer Institute, Northwell Health, New Hyde Park, NY, USA. 6. Cold Spring Harbor Laboratory, Cold Spring Harbor, Cold Spring, NY, USA. 7. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 8. Genomic Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Abstract
AIMS: TERT promoter mutations have been reported in 22% of solitary fibrous tumours (SFT) and have been associated with poor outcomes. We performed testing for TERT hot-spot mutations in a large series of SFT in order to confirm this finding and explore clinicopathological correlates of mutation status. METHODS AND RESULTS: PCR for TERT hot-spot mutations C250T and C228T was performed on DNA extracted from 216 SFT and mutation status correlated with clinicopathological factors, including predicted risk for metastasis using a previously published model. Testing was successful in 189 tumours from 172 patients, and mutations were present in 29%. The presence of TERT promoter mutation was associated with larger primary tumour size, necrosis and older patient age. TERT promoter mutations were most common in high-risk tumours (nine of 20, 45%), and were present in 11 of 26 (42%) moderate-risk tumours and 14 of 67 (21%) low-risk tumours (P = 0.004). Overall, TERT mutations were associated with shorter time to first metastasis (P = 0.04), but had no impact on overall survival. TERT promoter mutation status was found not to provide additional prognostic information in low- and high-risk SFT, but did identify a group of patients with intermediate risk SFT who had an increased risk of metastasis. CONCLUSIONS: TERT promoter mutations were more frequent in SFT with higher risk of metastasis, but TERT promoter mutation status was not a reliable predictor of clinical outcome by itself. However, mutations in the TERT promoter may be useful in further stratifying patients with intermediate risk tumours.
AIMS: TERT promoter mutations have been reported in 22% of solitary fibrous tumours (SFT) and have been associated with poor outcomes. We performed testing for TERT hot-spot mutations in a large series of SFT in order to confirm this finding and explore clinicopathological correlates of mutation status. METHODS AND RESULTS: PCR for TERT hot-spot mutations C250T and C228T was performed on DNA extracted from 216 SFT and mutation status correlated with clinicopathological factors, including predicted risk for metastasis using a previously published model. Testing was successful in 189 tumours from 172 patients, and mutations were present in 29%. The presence of TERT promoter mutation was associated with larger primary tumour size, necrosis and older patient age. TERT promoter mutations were most common in high-risk tumours (nine of 20, 45%), and were present in 11 of 26 (42%) moderate-risk tumours and 14 of 67 (21%) low-risk tumours (P = 0.004). Overall, TERT mutations were associated with shorter time to first metastasis (P = 0.04), but had no impact on overall survival. TERT promoter mutation status was found not to provide additional prognostic information in low- and high-risk SFT, but did identify a group of patients with intermediate risk SFT who had an increased risk of metastasis. CONCLUSIONS:TERT promoter mutations were more frequent in SFT with higher risk of metastasis, but TERT promoter mutation status was not a reliable predictor of clinical outcome by itself. However, mutations in the TERT promoter may be useful in further stratifying patients with intermediate risk tumours.
Authors: Hye Rhyn Chung; Kenric Tam; Albert Y Han; Farres Obeidin; Manando Nakasaki; Dinesh K Chhetri; Maie A St John; Ashley E Kita Journal: OTO Open Date: 2022-07-12
Authors: Isidro Machado; Gema Nieto Morales; Julia Cruz; Javier Lavernia; Francisco Giner; Samuel Navarro; Antonio Ferrandez; Antonio Llombart-Bosch Journal: Virchows Arch Date: 2019-09-16 Impact factor: 4.064
Authors: Wei-Lien Wang; Nalan Gokgoz; Bana Samman; Irene L Andrulis; Jay S Wunder; Elizabeth G Demicco Journal: Mod Pathol Date: 2020-10-02 Impact factor: 7.842